RxDoctor Payments Data

Eric Rosen, DO

Interventional Cardiology · Hollywood, FLNPI 1437390382

Payments from drug & device makers

$43,159in general payments, 2019–2025

Across 599 payments — averaging $72.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$30K
  • Cardiovascular Systems Inc.$3K
  • Johnson & Johnson$885
  • AstraZeneca$810
  • Amgen$732
  • Novartis$662
  • plus $6K from 48 others

What the payments were for

  • Consulting fees$14,57534%
  • Speaking & faculty fees$14,43033%
  • Travel & lodging$1,5334%
  • Food & beverage$12,57429%
  • Education$390%
  • Gifts$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,159 in reported general payments places this provider in the 75th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$304,950
Medicare patients
871
Services billed
3,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$44,511
BrilintaTicagrelor68$38,503
EntrestoSacubitril/Valsartan26$35,175
XareltoRivaroxaban32$27,643
Repatha SureclickEvolocumab35$21,862
Repatha SyringeEvolocumab19$14,342
ClopidogrelClopidogrel Bisulfate97$1,249
Atorvastatin Calcium77$994
Rosuvastatin Calcium81$787
Losartan Potassium69$524
Metoprolol Succinate29$436
Lisinopril48$351
Metoprolol Tartrate39$322
Ezetimibe26$294
Amlodipine Besylate44$268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$269$44,51137 claims
AstraZenecaBrilinta$810$38,50368 claims
NovartisEntresto$662$35,17526 claims
Johnson & JohnsonXarelto$885$27,64332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →